Thymosin Alpha-1 Dosage: Protocol, Timing & Clinical Evidence Guide

Overview

Thymosin alpha-1 (Tα1, trade name Zadaxin) is a 28-amino acid peptide derived from thymosin fraction 5, originally isolated from thymus tissue. It is the most extensively studied thymic peptide in human clinical trials, with an established regulatory history including approval in over 35 countries for hepatitis B, hepatitis C, and as an adjunct in cancer treatment. In the United States, thymosin alpha-1 is not FDA-approved but is prescribed off-label by functional and integrative medicine physicians, and is one of the more accessible peptides in the self-experimentation community due to its well-documented clinical dosing history. This guide provides a comprehensive, evidence-based overview of thymosin alpha-1 dosage, protocols, reconstitution, and clinical considerations derived from the published trial literature.

Standard Clinical Dose: Where 1.6 mg Comes From

The 1.6 mg twice-weekly subcutaneous dose that has become the standard in both clinical practice and self-experimentation is not arbitrary — it originates directly from Phase 2 and Phase 3 clinical trials conducted by SciClone Pharmaceuticals in the 1980s and 1990s for chronic hepatitis B and hepatitis C treatment. These trials established 1.6 mg as the minimum effective dose for immune modulation in chronic viral hepatitis, based on pharmacokinetic modeling and dose-response analysis. The twice-weekly frequency reflects thymosin alpha-1's biological half-life (approximately 2 hours in circulation following subcutaneous injection) and the observed immune response pattern — specifically, T-cell maturation and differentiation effects that require repeated pulsed stimulation rather than continuous exposure. Research in cancer patients used the same 1.6 mg dose twice weekly as an immunostimulatory adjunct during chemotherapy or radiation, where thymosin alpha-1 was administered to counteract treatment-induced immunosuppression. The safety profile at 1.6 mg is extensively documented across thousands of patient-years in these trials, which is why this dose is considered the clinical reference standard. Some more recent functional medicine protocols use 3.2 mg twice weekly (a doubling), and this higher dose appears in several anti-aging and chronic fatigue protocols. There is less clinical trial data supporting the higher dose in immune-competent individuals, and most community and clinical consensus remains anchored at 1.6 mg.

Loading Protocols: What Cancer and Hepatitis Research Used

Beyond the standard maintenance protocol, several clinical trial designs have used distinct loading phases or modified schedules worth understanding. The ENRICH trial and related oncology studies used thymosin alpha-1 in induction phases at higher frequency — occasionally daily for the first week — before transitioning to the standard twice-weekly schedule. This loading approach was aimed at rapidly establishing the immunological effect during a critical treatment window. The hepatitis C trials with interferon-alpha combination therapy used thymosin alpha-1 on the same 1.6 mg twice-weekly schedule for the entire 26-52 week treatment period, without a separate loading phase. These extended-duration studies (6-12 months) demonstrated sustained immunological effects without significant tolerance development or cumulative toxicity, which is an important finding for practitioners considering long-term protocols. For anti-aging and general immunomodulation purposes — the most common off-label use context — functional medicine physicians and the self-experimentation community have adapted these frameworks into cycles rather than continuous treatment, recognizing that indefinite use lacks an evidence base even where finite-cycle use is reasonably well-characterized.

Reconstitution Guide: Bacteriostatic Water, Volumes, and Calculations

Thymosin alpha-1 is supplied as a lyophilized (freeze-dried) white powder in sealed vials, typically in 1.0 mg, 1.5 mg, or 3.0 mg quantities. Proper reconstitution is critical for dosing accuracy and sterility. Here is the standard reconstitution protocol used by the clinical and self-experimentation community.

• Required materials: Lyophilized thymosin alpha-1 vials, bacteriostatic water for injection (BAW), appropriate insulin syringes (typically U-100, 28-31G), alcohol swabs, and a clean preparation surface.
• Bacteriostatic water volume: For a 1.5 mg vial, adding 1.5 mL of bacteriostatic water yields a concentration of 1.0 mg/mL, making dose calculations simple. A 1.6 mg dose then requires 1.6 mL (160 units on a U-100 syringe). For a 1.0 mg vial, add 1.0 mL for the same 1.0 mg/mL concentration.
• Alternative concentration for smaller injection volumes: For those who prefer smaller injection volumes, 1.0 mL of BAW in a 1.5 mg vial yields 1.5 mg/mL. A 1.6 mg dose then requires approximately 1.07 mL — slightly less convenient for calculation.
• Reconstitution technique: Clean the vial stopper with an alcohol swab. Insert the syringe needle at an angle to avoid bubbles. Inject the BAW slowly down the side of the vial rather than directly onto the peptide cake. Do not shake — gently swirl until the powder is fully dissolved.
• The solution should be clear and colorless. Any cloudiness, particulate matter, or unusual color indicates a problem — discard and do not inject.
• Storage after reconstitution: Refrigerate at 2-8°C (36-46°F). Protect from light. Discard after 28-30 days. Never freeze a reconstituted peptide solution — this damages the peptide structure.
• Lyophilized powder storage: Store in the freezer (−20°C) until ready to use. Lyophilized thymosin alpha-1 is stable for 12-24 months when properly frozen and sealed.

Injection Sites and Technique

Subcutaneous (SC) injection is the only route used in clinical trials for thymosin alpha-1, and it is the community standard. Intramuscular administration is not necessary and offers no pharmacokinetic advantage. Proper subcutaneous technique minimizes discomfort and ensures consistent absorption.

• Preferred injection sites: Lower abdomen (approximately 2 inches from the navel, avoiding the midline), outer thigh (front or side, middle third), and upper outer buttock. The abdomen is the most commonly used site due to accessibility and consistent subcutaneous fat depth.
• Rotation: Rotate injection sites systematically to avoid lipodystrophy (fat tissue changes from repeated injections at the same site). A common rotation pattern is left abdomen → right abdomen → left thigh → right thigh on successive injections.
• Needle selection: 28-31G, 4-8mm needle length is appropriate for most individuals with adequate subcutaneous fat. A longer needle may be needed for individuals with minimal abdominal fat to ensure SC (not intramuscular) delivery.
• Injection speed: Inject slowly over 3-5 seconds after aspiration (gently pull plunger back slightly — absence of blood confirms non-vascular placement). Apply gentle pressure with a dry swab after withdrawal; do not rub, which can cause subcutaneous bruising.
• Timing: Thymosin alpha-1 does not have a specific time-of-day requirement based on clinical data. Most users administer in the morning for logistical convenience. Consistent timing on both injection days of the week (e.g., Monday and Thursday) helps maintain the twice-weekly schedule.

Cycle Length: Clinical Evidence and Practical Protocols

The appropriate thymosin alpha-1 cycle length depends significantly on the indication. Clinical trial evidence provides guidance for the most common use cases.

• Short cycle (4 weeks): Used for acute immune support during illness, post-surgery recovery, or during intensive training/stress periods. Not the most common approach in clinical trials but reasonable based on the immunological response timeline.
• Standard cycle (6-8 weeks): The most common approach in functional medicine settings for general immune optimization, post-viral syndrome support, or anti-aging protocols. Provides enough time to observe immunological effects (typically noted at 4-6 weeks) while keeping cycle length manageable.
• Hepatitis C protocol (24-52 weeks): Clinical trials combined thymosin alpha-1 with interferon for 24-52 week treatment courses. This extended duration is specific to chronic viral hepatitis treatment and is not generally applied to wellness or anti-aging contexts.
• Cancer immunostimulation (throughout treatment): Several oncology trials continued thymosin alpha-1 throughout the entire chemotherapy or radiation course (potentially months), with the goal of maintaining immune function during immunosuppressive treatment.
• Rest periods: For non-disease wellness applications, most functional medicine protocols include an off-cycle of 4-8 weeks between 6-8 week cycles. This approach is pragmatic rather than strictly evidence-based — the clinical trials in hepatitis and cancer used continuous administration without breaks.
• Monitoring: For multi-cycle protocols, baseline and follow-up lymphocyte subset panels (CD4/CD8 counts, NK cell activity) are recommended where accessible to objectively assess immune response.

Cost and Sourcing Considerations

Thymosin alpha-1 cost varies significantly depending on the supply channel. Here is a realistic breakdown of what individuals report paying through different sourcing pathways. Clinic-prescribed thymosin alpha-1 through US compounding pharmacies typically costs $300-$500/month for a standard 1.6 mg twice-weekly protocol. This includes the compounding pharmacy cost and generally incorporates prescriber oversight. SciClone's branded Zadaxin is approved in over 35 countries and is available at pharmacies in Southeast Asia, Eastern Europe, and Latin America at prices ranging from $50-$150 per 1.6 mg vial — still a significant cost for a full cycle but far below US compounding prices. Zadaxin from legitimate international pharmacies with prescription documentation is considered by the community to be the highest quality available supply of thymosin alpha-1. Research-grade thymosin alpha-1 from peptide vendors ranges from $30-$80 per vial (typically 1-5 mg lyophilized) depending on the vendor and quantity. Quality varies significantly, and the standard community advice applies: verify COAs with HPLC and mass spectrometry, choose vendors with published batch testing, and be appropriately skeptical of unusually cheap pricing. For a standard 6-week cycle at 1.6 mg twice weekly, you need approximately 12 vials of 1.6 mg each (or equivalent), totaling about $350-$960 through clinics or $60-$120 through research vendors.

Clinical Benefits and Evidence Summary

Understanding the evidence base for thymosin alpha-1 helps contextualize when and for whom it is most likely to be beneficial. The strongest evidence — from randomized controlled trials — comes from specific disease contexts.

• Hepatitis B: Multiple Phase 3 trials demonstrated thymosin alpha-1 reduces HBV DNA levels and increases rates of HBeAg seroconversion compared to placebo. Meta-analyses confirm this effect, though combination with antiviral drugs is now standard of care.
• Hepatitis C: Combined with interferon-alpha, thymosin alpha-1 improved sustained virological response rates in several trials, particularly in patients who were interferon non-responders. Direct-acting antivirals have largely supplanted this indication.
• Cancer immunostimulation: Several randomized trials in lung, hepatocellular, and other cancers showed thymosin alpha-1 reduced chemotherapy-induced immunosuppression markers and in some studies improved survival endpoints. The most cited study (ENRICH trial in NSCLC) showed improved overall survival in the thymosin alpha-1 arm.
• COVID-19/critical illness: Studies from China during the COVID-19 pandemic reported reduced mortality and faster recovery in critically ill patients treated with thymosin alpha-1, though study quality varied. This spurred significant renewed interest in the compound.
• Off-label wellness use (anti-aging, chronic fatigue, general immunity): This is the most common current use context, but the evidence base is weakest here. There are no randomized controlled trials demonstrating benefit for immune "optimization" in healthy individuals.

Who Should NOT Use Thymosin Alpha-1

Thymosin alpha-1's immunostimulatory mechanism makes it potentially contraindicated or requiring caution in specific populations. This is a critical safety consideration that is sometimes underemphasized in community discussions.

• Active autoimmune disease: Individuals with conditions like rheumatoid arthritis, lupus (SLE), multiple sclerosis, inflammatory bowel disease, or other active autoimmune conditions should generally avoid thymosin alpha-1. Stimulating immune activity in an already dysregulated immune system can exacerbate inflammation and disease activity. There are isolated reports of autoimmune flares following thymosin alpha-1 use in community threads.
• Organ transplant recipients on immunosuppression: Thymosin alpha-1's immune-enhancing effects directly oppose the goal of post-transplant immunosuppression. Use in this population could contribute to rejection.
• Active hypersensitivity reactions: Thymosin alpha-1 should not be used during active allergic reactions or anaphylaxis, as immune stimulation during active hypersensitivity may worsen the response.
• Pregnancy and lactation: No adequate safety data exists for thymosin alpha-1 in pregnancy or breastfeeding. Clinical trials excluded these populations, and use during pregnancy cannot be recommended.
• Pediatric populations: Most clinical trial data is in adults. Use in children without specific medical indication and physician supervision is not warranted.
• Concurrent immunostimulatory medications: Combination with other immune-modifying biologics (checkpoint inhibitors, IL-2, interferons) should only occur under physician supervision due to additive immune activation risks.
• Theoretical concern with malignancy: Some oncologists express caution about thymosin alpha-1 use in cancer patients outside of the studied contexts, as immune activation in the context of an established tumor is not uniformly beneficial and could theoretically influence tumor biology. Consult an oncologist before use.

References

1. Thymosin Alpha 1 (Zadaxin): A Peptide Immunomodulator for Restoration of Immune Function (2005) — PubMed
2. Thymosin-Alpha 1 in the Treatment of Hepatitis B and C: A Meta-Analysis (2010) — PubMed
3. ENRICH Trial: Thymosin Alpha-1 in Combination with Chemotherapy for NSCLC (2013) — PubMed
4. Thymosin Alpha-1 Efficacy and Safety in COVID-19 Patients: A Systematic Review (2021) — PubMed
5. Pharmacokinetics and Pharmacodynamics of Thymosin Alpha-1 in Healthy Subjects (1991) — PubMed